Tevogen Bio released a letter to stockholders and said it is exploring a potential share buyback. The letter states in part, “Our lead product candidate TVGN 489, an investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocyte immunotherapy, is progressing for the treatment of acute COVID-19 in vulnerable cancer patients. Phase I clinical trial results of TVGN 489, have recently been published by Blood Advances, a peer reviewed journal. A trial aimed at identifying genetic characteristics, potentially leading to Long COVID, has been prepared and could serve as a basis for a later treatment trial…In light of recent stock performance, we understand the concerns some of you may have regarding Tevogen Bio’s current share price. We are acutely aware of the situation and our commitment to improving stockholder value remains steadfast. We are considering available options, including the potential for a share repurchase, to enhance the value of your investment.”
previous post